{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "CERS",
  "name": "Cerus Corporation",
  "url": "https://orbyd.app/dossiers/CERS/",
  "json_url": "https://orbyd.app/dossiers/CERS.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Analyst-confirmed profitability inflection (Q1'26 adj-EBITDA +$4.0M, +24% product rev) in a 25-year blood-safety grinder, but the 2.7x off the lows is largely spent and price sits near 52-week highs (~$3.00). The 2026-07-30 Q2 print is now the imminent binary — a MATURING pullback name into an earnings blackout, not a chase at the range high.",
  "invalidation_trigger": "A weekly close below $2.70 loses the rising 20-week EMA that has guided the entire advance and breaks the turnaround structure; secondary: an FY26 product-revenue guide cut below the ~$227M floor on the 2026-07-30 Q2 print, adjusted EBITDA flipping back negative, or a negative RedeS Phase 3 RBC readout.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "precision-biotech-therapeutics",
    "small-cap-value-rotation"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Liquidity ~$80.4M (cash $27.85M + ST investments $52.6M as of 2026-03-31); adj-EBITDA-positive status reduces dilution overhang. Market cap ~$575M (2026-07-24).",
    "Analyst tape: BTIG Buy/$4 (2026-05-01), consensus Strong Buy; 12-month avg PT clustered $4.00-4.67, high $5.00, low ~$2.50-3.00.",
    "CEO transition effective 2026-07-01: Vivek Jayaraman (ex-COO/CCO) now President & CEO; Greenman to executive chairman. Jayaraman grew product rev from <$40M to >$200M by 2025.",
    "Commercial wins: 4-year EFS (French Blood Establishment) supply deal for INTERCEPT platelets/plasma + INT200; Blood Centers of America GPO agreement (US INTERCEPT access).",
    "Concrete negative: EU CE Mark for INTERCEPT RBC concluded WITHOUT approval — company reassessing filing strategy; red-cell leg in Europe stalled.",
    "Forward catalysts: INT200 PMA submission ~mid-2026 (imminent/overdue); RedeS Phase 3 RBC readout H2-2026 (binary).",
    "Governance: activist Bradley L. Radoff (2026-05-27) signaled withhold-vote intent over dilution/profitability; resolved via chairman shuffle but shareholder base is impatient.",
    "MATURING legacy-pivot, not an ACCELERATING cluster setup — accumulate on 20-week-EMA pullback (mid-$2.70s and rising), not at range highs. Research/watch only."
  ],
  "body_markdown": "## Current Thesis\nThe leg an investor would be buying is a **profitability inflection in a 25-year-old blood-safety grinder that the sell-side has already confirmed** — not a fast-moving momentum theme. The 2026-04-30 Q1 print delivered the event that historically caps this name: total revenue $59.9M (+23% YoY), product revenue $53.7M (+24% YoY), a net loss of $0.01/sh against −$0.04 consensus, adjusted EBITDA +$4.0M and operating cash flow +$6.2M — the quarter where the cash, not just the adjusted line, showed up. Management lifted FY26 product-revenue guidance to $227–231M (+10–12% YoY), BTIG upgraded to Buy/$4 on 2026-05-01, and two commercial wins landed inside the quarter. Most of that re-rate has played out: the stock ran ~2.7x from a $1.15 52-week low to a $3.21 high, then eased back toward ~$3.00 (market cap ~$575M as of 2026-07-24) as the Q2 print approaches. The read has changed materially since the last refresh in one respect — **the Q2 2026 report is now confirmed for Thursday, 2026-07-30 after the close (4:30pm ET call), roughly three trading days out.** What was \"no catalyst before the late-July print\" is now an imminent binary into an earnings blackout. This is a **MATURING** legacy pivot at the top of its range; the clean setup is accumulation on a pullback to the rising 20-week EMA, and the near-term stance is to stand aside rather than buy into the print.\n\n## Bull Case\n- **The cash turned, not just the adjusted line.** Q1'26 (2026-04-30): adjusted EBITDA +$4.0M and operating cash flow +$6.2M, net loss collapsing to −$0.01/sh vs −$0.04 consensus. A perennial cash-burner beginning to self-fund removes the standing dilution overhang.\n- **Beat-and-raise with lagging analyst confirmation.** FY26 product-revenue guide raised to $227–231M (+10–12% YoY) on +24% product growth. BTIG moved to Buy/$4 on 2026-05-01; consensus is now Strong Buy with a 12-month average target clustered $4.00–4.67 (high $5.00) — targets sitting 30%+ above the tape, trailing the move rather than front-running it.\n- **Two commercial wins in one quarter.** A four-year Établissement Français du Sang supply agreement (INTERCEPT platelets/plasma + the next-gen LED INT200 illuminator) and a Blood Centers of America group-purchasing deal widened U.S. and French access, with INTERCEPT Fibrinogen Complex as the higher-value demand driver on the legacy platelet-kit base.\n- **Leadership transition executed on schedule.** Vivek Jayaraman (former COO/CCO) became President & CEO effective 2026-07-01, with Greenman moving to executive chairman. Jayaraman ran the growth from <$40M product revenue to >$200M (2025); a fresh operator inheriting a newly cash-positive small-cap sets up a plausible operational-discipline or strategic-review path.\n- **Balance sheet supports the pivot.** Liquidity ~$80.4M (cash $27.85M + short-term investments $52.6M, 2026-03-31) against a ~$575M market cap; adjusted-EBITDA-positive status lowers future dilution risk.\n- **Free optionality on the red-cell franchise.** RedeS Phase 3 RBC readout due in H2'26, INT200 PMA submission targeted ~mid-2026, and a BARDA-funded red-cell program — a positive readout opens a materially larger TAM at no cost to the base case.\n\n## Bear Case\n- **The move already happened.** ~2.7x off the $1.15 low to the $3.21 high, now cooling into the print near ~$3.00. An entry here buys the back half of a turnaround the tape has already digested.\n- **This is a grinder, not a narrative rocket.** A +10–12% product-revenue grower carries no velocity; there is no peer cluster breaking out alongside it, so there is no cluster-confirmation setup to lean on.\n- **The red-cell leg took a concrete hit.** The EU CE Mark for INTERCEPT RBC concluded WITHOUT approval and the company is reassessing its filing strategy — a real negative on the higher-TAM franchise that bulls treat as free optionality.\n- **Binary print into an expensive tape.** The Q2 report (2026-07-30) lands with the stock near 52-week highs and consensus already at Strong Buy; a guide that merely reaffirms the $227–231M range, or any adjusted-EBITDA slippage, is a sell-the-news risk with limited room to re-rate higher.\n- **RedeS is a genuine binary.** A negative H2'26 Phase 3 readout removes the entire red-cell optionality and re-anchors the story to a single-digit-growth core.\n- **Governance friction is on file.** Activist Bradley L. Radoff signaled intent (2026-05-27) to withhold votes from Greenman and the comp-chair over dilution and profitability — resolved cosmetically by the chairman shuffle, but a marker that the shareholder base is impatient.\n\n## Setup & Price Structure\nPrice sits at the top of a 52-week range ($1.15–$3.21), having drifted from the $3.19–$3.21 highs (early July) back toward ~$3.00 into the print. The advance has ridden a rising 20-week EMA the entire way; that EMA is the structural spine of the trade. RSI on the weekly ran hot near the highs (the name was flagged in a 2026-05-20 overbought screen) and has cooled with price. This is not an accelerating breakout that gaps away from support — it is a maturing uptrend that periodically retests its moving average. The favorable entry is a pullback into the rising 20-week EMA (roughly the mid-$2.70s–$2.80s and climbing), not a chase at the range high three trading days before a binary earnings event. A weekly close that loses the rising 20-week EMA would break the turnaround structure and convert the \"cheap pivot\" thesis into a value trap. Beginner-trap read: this is squarely in \"earnings in <3 days\" and \"stretched near range highs\" territory — the two conditions that most reliably punish fresh entries in a slow-grower.\n\n## Catalyst Calendar (next 30 days)\n\n- **~mid-2026 (imminent/overdue):** INT200 next-gen illuminator PMA submission in the U.S. a management progress note is plausible on the 07-30 call.\n- **Post-print, ~2026-07-31 to ~2026-08-10:** Analyst revision cluster (BTIG, Zacks, Wall Street Zen) — direction of estimate revisions confirms or breaks the acceleration read.\n- **H2-2026 (outside 30d, flagged):** RedeS Phase 3 RBC readout — the genuine binary for the red-cell franchise.\n\n## Elapsed catalysts\n\n- **2026-07-30 (confirmed):** Q2 2026 financial results, after market close, conference call 4:30pm ET. The binary of the window. Watch: FY26 product-revenue guide (reaffirm/raise vs the $227–231M range), adjusted EBITDA sign, operating cash flow, and any RedeS/INT200 timeline update. *(passed 10d ago)*\n\n## What Would Change Our Mind\n- **Structure break:** A weekly close below $2.70 loses the rising 20-week EMA and the turnaround structure — the level that would flip this from \"buy the pullback\" to \"stand aside.\"\n- **Guide cut:** An FY26 product-revenue guide trimmed below the ~$227M floor on 2026-07-30, or adjusted EBITDA flipping back negative, breaks the profitability-inflection thesis outright.\n- **Red-cell failure:** A negative RedeS Phase 3 readout removes the optionality leg and caps the multiple on a low-double-digit grower.\n- **Re-acceleration (bullish flip):** A raised FY26 guide north of $231M with sustained positive operating cash flow and a clean RedeS/INT200 timeline would upgrade this from a pullback-only name toward a growth re-rate worth chasing.\n\n## Correlation Notes\nCERS trades as an idiosyncratic small-cap blood-safety story with low read-through to broad indices; the dominant driver is company-specific catalyst flow (guidance, RedeS, INT200), not sector beta. Sensitivities worth tracking: small-cap risk appetite (Russell 2000/IWM) since a ~$575M-cap name gets valued off liquidity conditions; med-tech/diagnostics peer sentiment as a secondary tell; and — for the red-cell leg — regulatory/reimbursement headlines in transfusion medicine. There is no clean listed peer that co-moves tightly enough to use as cluster confirmation, which is precisely why this is a single-name situation rather than a theme trade. FX matters at the margin given European (EFS/France) revenue exposure, though the effect is small relative to catalyst risk.",
  "first_seen": "2026-05-20",
  "last_analyzed": "2026-07-26T12:08:07+00:00",
  "last_synthesized": "2026-07-26",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}